Introduction
============

The vast majority of intracranial cancer metastasis occurs in the brain parenchyma, and metastasis to choroid plexus is rare. Common pure intraventricular tumors are meningiomas and choroid plexus papillomas/carcinomas, and metastasis is not ranked high on the list of differential diagnosis. Here we report a metastatic tumor to the choroid plexus from a thyroid cancer, which is not a common cause of intracranial metastasis.

Case Report
===========

A 74-year-old woman with a history of hypertension but not of any malignancy presented with vertigo, memory loss, and clumsiness in the left hand that had gradually worsened by 2 months. Neurological examination detected no focal neurological deficit. Magnetic resonance imaging (MRI) showed a well demarcated, 4 cm in diameter, heterogeneously enhancing mass in the right lateral ventricle trigone ([Fig. 1](#F1){ref-type="fig"}). Cerebral angiography demonstrated a hypervascular mass supplied from both anterior and posterior choroidal arteries. A meningioma was suspected, but the heterogeneous enhancement prompted us to screen for systemic malignancy by whole body computed tomography (CT) scan that revealed multiple nodules in the lung, a destructive lesion at the right dorsal rib, and a slightly enlarged thyroid gland with calcification. Preoperative differential diagnosis included meningioma, choroid plexus carcinoma, and metastasis. Considering the high vascularity of the tumor, open biopsy of the tumor via parietal transcortical approach was performed. The tumor consisted of soft tissue containing yellowish and reddish portions, and caused profuse bleeding when incised. On histological examination, the tumor demonstrated follicular structure containing colloidal substances ([Fig. 2](#F2){ref-type="fig"}). Immunohistochemistry showed that the colloidal substance was positive for thyrogloblin and thyroid transcription factor-1, confirming the diagnosis of thyroid carcinoma metastasis. Considering the general status and the risk of resection of the highly hemorrhagic tumor, the patient underwent local radiation therapy with 60 Gy, and the MRI obtained 1 month after the radiation treatment demonstrated slight shrinkage of the mass. The patient further underwent thyroid tumor resection, followed by systemic radiation therapy using radioactive iodine (RAI). Two months after surgery, MRI of the brain showed enhancement along the biopsy tract suggesting possible dissemination, and 15 Gy of whole brain radiation therapy was performed. The intraventricular mass gradually lost enhancement, and MRI obtained 14 months after surgery showed complete central necrosis with rim enhancement, with the patient remaining in stable neurologically ([Fig. 3](#F3){ref-type="fig"}).

Discussion
==========

Thyroid cancer accounts for about 1% of newly diagnosed malignant neoplasms, of which 94% are differentiated thyroid cancer of either papillary or follicular type. Both types show relatively benign clinical course with 10-year survival exceeding 80% and 50%, respectively. When metastasize, the papillarly cancer usually develops lymphogenous metastasis to lymph nodes, while the follicular type mostly causes hematogenous metastasis to lung and bones. Thyroid cancer metastasis to the central nervous system is rare, with only 0.9--1.5% of brain metastasis being reported to be from the thyroid cancer.^[@B3],[@B26],[@B33]^

In the present case, the tumor was a purely intraventricular mass without obvious attachment to the ventricular wall, and rich blood supply from the anterior and posterior choroidal arteries were observed. Therefore, the choroid plexus was the probable site of the metastasis. Choroid plexus is not a frequent site of the metastasis, and we could find only 33 such cases in the literature ([Table 1](#T1){ref-type="table"}).^[@B1],[@B2],[@B4]--[@B14],[@B16]--[@B18],[@B20]--[@B24],[@B27]--[@B33]^ Of those 33 cases, 14 cases (42%) were from kidney, 4 were from colon, and 6 (18%) were from lung cancer. Considering that more than 16.3% of brain metastases are from lung cancer while kidney accounts for only 9.8%,^[@B25]^ there seems to be clear tendency for kidney cancer to preferentially metastasize to choroid plexus. Similarly, 9% (3 of 33 including the present case) prevalence of thyroid cancer as the origin of choroid plexus metastasis also suggest that thyroid cancer cells might have some biological affinity to choroid plexus, demonstrating an example of the seed and soil relationship.^[@B15]^ Neurological symptom for those cases are mostly non-localizing, with headache or consciousness disturbance caused by increased intracranial pressure being the common presentation. Probably reflecting the notorious tendency of thyroid cancer for bleeding, intratumoral hemorrhage can be the onset of the symptoms ([Table 1](#T1){ref-type="table"}).^[@B32]^

Although patients with papillary thyroid cancer can expect 10-year survival of more than 90%, the rate drops to 30% to 50% in patients with lung metastasis. For those with brain metastasis, median survival is reported to be only 12.4 months.^[@B19],[@B26]^ McWilliams et al. studied the cases of 16 patients with brain metastasis from thyroid cancer, and reported that surgical resection of the brain lesion was associated with longer survival (20.8 months vs 2.7 months).^[@B19]^ Addition of stereotactic radiosurgery to the residual tumor after partial surgical resection improved the prognosis (31.3 months vs 12.8 months). Administration of RAI was also effective while the benefit was rather marginal (18.4 months with RAI and 13.6 months without RAI).^[@B33]^ When the lesion was resected, there was no clear benefit of whole brain radiation therapy. Therefore, when feasible, total resection of the lesion is the treatment of choice for thyroid cancer metastasis to the brain. In our case, however, the large size, location, and the hypervascularity of the lesion led to the decision to perform biopsy and radiation therapy to follow.

In summary, we reported a large ventricular tumor caused by thyroid cancer metastasis to the choroid plexus. Choroid plexus metastasis is a rare event and the number of reported cases is still small, but kidney and thyroid cancer seems to have higher tendency to metastasize to choroid plexus and hence should be included in the list of differential diagnosis when such lesions are encountered.

![(a) Axial and (b) coronal view of gadolinium-enhanced magnetic resonance imaging (MRI) demonstrating a well-demarcated tumor within the lateral ventricle.](nmc-53-832-g1){#F1}

![Microscopic appearance of the tumor. a: Haematoxylin-eosin stain and b: immunohistochemistry for thyroglobulin demonstrate thyroid cancer metastasis.](nmc-53-832-g2){#F2}

![Gadolinium-enhanced magnetic resonance imaging (MRI) obtained 14 months later demonstrates necrosis of the tumor without growth.](nmc-53-832-g3){#F3}

###### 

Summary of 33 cases of matastasis to the choroid plexus

  Author (year)                       Age/Sex   Primary     Location           Presenting symtoms
  ----------------------------------- --------- ----------- ------------------ ----------------------------------
  Killebrew et al. (1983)^[@B12]^     55/F      Kidney      L. trigone         headache
  Kendal et al. (1983)^[@B11]^        ?/F       Breast      R. trigone         
  [@B11]                              ?/F       Skin        4th ventricle      
  Kart et al. (1986)^[@B10]^          61/M      Lung        L. trigone         
  Shigemori et al. (1987)^[@B27]^     58/M      Kidney      Body of R.LV       headache
  Fukui et al. (1990)^[@B6]^          53/F      Lymphoma    R. trigone         headache
  Tanimoto et al. (1991)^[@B31]^      64/M      Lung        R. trigone         headache
  Mizuno et al. (1992)^[@B20]^        59/M      Kidney      Body of L.LV       headache
  Nakabayashi et al. (1994)^[@B22]^   64/M      Stomach     Body of L.LV       consiousness dist.
  Suetake et al. (1994)^[@B29]^       78/M      Kidney      Body of L.LV       consiousness dist.
  Spetzger et al. (1995)^[@B28]^      60/F      Kidney      4th ventricle      headache
  Kohno et al. (1996)^[@B14]^         66/M      Kidney      R. trigone         hemiparesis. disorientation
  [@B14]                              66/M      Lung        R. inferior horn   seizures
  [@B14]                              45/M      Colon       L. trigone         hemiparesis
  Matsumura et al. (1997)^[@B18]^     68/M      Kidney      Body of R.LV       headache
  Raila et al. (1998)^[@B24]^         47/F      Kidney      R. trigone         headache
  Arbelaez et al. (1999)^[@B2]^       48/F      Skin        L. trigone         headache
  I watsuki et al. (1999) ^[@B8]^     75/F      Kidney      L. trigone         headache, consiousness dist.
  Qasho et al. (1999)^[@B23]^         40/M      Bladder     R. trigone         seizures
  Ai-Anazi et al. (2000)^[@B1]^       81/M      Colon       Bil ventriclars    headache
  Motoyama et al. (2000)^[@B21]^      70/F      Kidney      L. trigone         headache
  Escott et al. (2001)^[@B5]^         32/M      Skin        L. trigone         headache
  Hillard et al. (2003)^[@B7]^        54/F      Kidney      L. trigone         headache
  Kitajima et al. (2003)^[@B13]^      48/F      Colon       R. ineror horn     headache
  Kadrian et al. (2004)^[@B9]^        54/F      Kidney      L. trigone         headache
  Leach et al. (2004)^[@B17]^         50/F      Colon       3rd ventricle      headache
  [@B17]                              43/F      Kidney      3rd ventricle      personality & behavioral changes
  Lauretti et al. (2005)^[@B16]^      65/F      Kidney      Body of R.LV       headache
  Sung et al. (2006)^[@B30]^          42/M      Esophagus   3rd ventricle      unsteady gait
  Zang et al. (2009)^[@B33]^          62/M      Thyroid     R. trigone         memory loss
  Della Puppa et al. (2010)^[@B4]^    66/F      Breast      L. trigone         aphasia
  Wasita et al. (2010)^[@B32]^        75/M      Thyroid     Body of R.LV       headache
  Present case (2012)                 74/F      Thyroid     R. trigone         memory loss

LV: lateral ventricle.
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